Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.63 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | GGT1 | P19440 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diaspirin SCHEMBL30735506 | 1.00 | KDM4E (0.75) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL12446248 | 0.94 | KDM4E (0.69) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL3765406 | 0.92 | KDM4E (0.81) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL27531407 | 0.91 | KDM4E (0.66) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL14494719 | 0.91 | KDM4E (0.69) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL13109053 | 0.91 | KDM4E (0.79) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL973615 | 0.91 | KDM4E (0.79) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL1697677 | 0.89 | KDM4E (0.82) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL22279480 | 0.89 | KDM4E (0.67) | KDM4EKMT2AMEN1RECQLHSD17B10 | |
| SCHEMBL25946877 | 0.89 | KDM4E (0.67) | KDM4EKMT2AMEN1RECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492585-B1 | METHOD FOR PRODUCING MESENCHYMAL STEM CELLS THAT INHIBIT PROLIFERATION OF CANCER CELLS | RA JEONG CHAN (KR) | 2026-02-18 | — | — | EP | claimed |
| CN-114036796-A | Shear band expansion method considering uneven reduction of seabed slope soil strength | 中国海洋大学 | 2022-02-11 | — | — | CN | claimed |
| EP-1358212-B1 | METHODS FOR THE SYNTHESIS OF A MODIFIED HEMOGLOBIN SOLUTION | BREONICS INC (US) | 2014-04-30 | — | — | EP | claimed |
| EP-2600155-A1 | sFlt-1 based diagnosis and monitoring of stroke patients | Roche Diagniostics GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| EP-1163010-B1 | HEMOGLOBIN-ANTIOXIDANT CONJUGATES | THERAPURE BIOPHARMA INC (CA) | 2012-12-12 | — | — | EP | claimed |
| WO-2011075799-A2 | ORAL ANTIDEPRESSANT FORMULATION | MENDLEWICZ JULIEN (BE) | 2011-06-30 | — | — | WO | claimed |
| US-20100311641-A1 | PEPTIDE-BASED BODY SURFACE COLORING REAGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | claimed |
| US-20100189797-A1 | ORAL ANTIDEPRESSANT FORMULATION | MENDLEWICZ JULIEN | 2010-07-29 | — | — | US | claimed |
| US-7662805-B2 | Mixture of antidepressant such as serotonine receptor antagonist, with acetylsalicylic acid | MENDLEWICZ JULIEN | 2010-02-16 | — | — | US | claimed |
| EP-1677772-B1 | ORAL ANTIDEPRESSANT FORMULATION COMPRISING ACETYLSALICYLIC ACID TO ACCELERATE ONSET OF ACTION | KRIWIN PHILIPPE (BE) | 2009-08-26 | — | — | EP | claimed |
| WO-1996015805-A1 | HEMOGLOBIN THERAPY IN HEMODIALYSIS | BAXTER INTERNATIONAL INC. (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0700298-A1 | THERAPEUTIC USE OF HEMOGLOBIN IN THE TREATMENT OF BLOOD VESSEL BLOCKAGE | BAXTER INTERNATIONAL INC. (a Delaware corporation) (US) | 1996-03-13 | — | — | EP | claimed |
| WO-1995026195-A1 | THERAPEUTIC USE OF HEMOGLOBIN IN THE TREATMENT OF BLOOD VESSEL BLOCKAGE | BAXTER INTERNATIONAL INC. (US) | 1995-10-05 | — | — | WO | claimed |
| US-5248766-A | Oxirane-modified hemoglobin based composition | BAXTER INTERNATIONAL INC. (US) | 1993-09-28 | — | — | US | claimed |
| EP-0496866-A1 | HEMOGLOBIN-OLIGOMER BASED COMPOSITION AND METHOD TO MAKE SAME. | BAXTER INT (US) | 1992-08-05 | — | — | EP | claimed |
| WO-1992003153-A1 | HEMOGLOBIN-OLIGOMER BASED COMPOSITION AND METHOD TO MAKE SAME | BAXTER INTERNATIONAL INC. (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0143832-B1 | MODIFIED CROSSLINKED STROMA-FREE TETRAMERIC HEMOGLOBIN | TYE, Ross W. (US) | 1989-02-15 | — | — | EP | claimed |
| US-4529719-A | Modified crosslinked stroma-free tetrameric hemoglobin | TYE ROSS W (US) | 1985-07-16 | — | — | US | claimed |
| US-4474750-A | Anticalculus oral composition | COLGATE-PALMOLIVE COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| US-4080441-A | BIS(O-CARBOXYPHENYL)ESTER OF AN ALIPHATIC DICARBOXYLIC ACID USED AS AN ANTISTAIN AGENT | COLGATE-PALMOLIVE COMPANY (US) | 1978-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311641-A1 | PEPTIDE-BASED BODY SURFACE COLORING REAGENTS | CUTA, PRAP1, RBP1 | KDM4E 4802/4885KMT2A 3436/4885MEN1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.